Trial Profile

A Phase 1/2, Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 After Complete Resection of Stage IIIB/IIIC/IIID or Stage IV Melanoma in Patients at High Risk for Recurrence

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Nov 2024 According to a Evaxion media release, poster from this study will be presented by Gregg Wilson, PhD, RN, Director of Medical and Scientific Affairs, on Nov 8, 2024 at the Society of Immunotherapy of Cancer (SITC) conference, which will be held at the George R. Brown Convention Center in Houston, Texas.
21 Feb 2024 Status changed from active, no longer recruiting to discontinued.
31 May 2023 According to a Evaxion media release, full read from this study will be presented at the American Society for Clinical Oncology (ASCO) Meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com